TBPH
NASDAQ · Pharmaceuticals
Theravance Biopharma Inc
$14.33
+0.32 (+2.28%)
Financial Highlights (FY 2026)
Revenue
66.62M
Net Income
-58,378,188
Gross Margin
100.0%
Profit Margin
-87.6%
Rev Growth
+5.2%
D/E Ratio
0.17
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 61.7% | 61.7% |
| Operating Margin | -72.9% | -65.6% | 15.8% | 13.6% |
| Profit Margin | -87.6% | -83.3% | 12.8% | 13.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 66.62M | 63.32M | 591.55M | 658.39M |
| Gross Profit | 66.62M | 63.32M | 364.96M | 406.20M |
| Operating Income | -48,577,001 | -41,558,270 | 93.68M | 89.66M |
| Net Income | -58,378,188 | -49,943,316 | 75.68M | 89.76M |
| Gross Margin | 100.0% | 100.0% | 61.7% | 61.7% |
| Operating Margin | -72.9% | -65.6% | 15.8% | 13.6% |
| Profit Margin | -87.6% | -83.3% | 12.8% | 13.6% |
| Rev Growth | +5.2% | +5.2% | +8.8% | -5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 73.39M | 73.39M | 481.91M | 528.63M |
| Total Equity | 424.72M | 424.72M | 471.86M | 413.39M |
| D/E Ratio | 0.17 | 0.17 | 1.02 | 1.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -46,808,693 | -42,270,207 | 125.32M | 145.74M |
| Free Cash Flow | — | — | 94.80M | 134.21M |